Talon Therapeutics Inc (fka TLON)

[operating_line]

We need to see a milestone being met to trigger a payment.

There should be study results on Marqibo next year for the US and we can see some signs of potential for China. I do not see what SEC can do here. One could write to a broker who can confirm with the transfer agent that the CVRs remain active.

With just a few of us, class action might not lead to much unless you can see something that shows evidence of us all being misled. As far I can see, they did not have the funds to commercialize this and sold it off at a fraction of what it is worth. I have my CVRs stuck in a large institution but I will not forget about my 115k TLON CVRs.

[CVR Investor]

I think we should call the SEC. I still see my mine on Td ameritrade. Ever since scottrade sold its self.

Let me know what action you want to take. I think I will do the same as well.

It's very tricky because Spectrum sold Marquibo to Acrotech Biopharma L.L.C.. We need our money for this sell.

[CVR Investor]

@Operating_line - It's a long time waiting. 7 YEARS!~

I still think we should do a class action lawsuit.

[FLY HIGH NOW]

Any brokers Can’t Remove the Stocks with Waiting CVRs ? That is Illegal ? We TLON can Request our Brokers keep our CVRs of TLON on our Accounts? If brokers Remove TLON on our Accounts, later we should receive our Money from our CVRs of TLON... then our brokers Not put Our money in our accounts because they will say they don’t see TLON on our Accounts?? What all TLON investors here think and have any experiences from other Stocks and /or brokers??? We all TLON investors have 20 years to Wait for our CVRs coming?? Please share??????do we need to Contact SEC? Specteum? Our lawyers?! ... about our Long Waiting CVRs?

[operating_line]

yes, I give it a low chance of payoff also but will check on it later. good luck

[ErnieBilco]

Really doesn't hurt me since I wrote off that account long ago even though some tickers remain nothing worth my time or effort. I still hold some in 3 other accounts should something happen but not expecting anything considering the way Talon shit on shareholders to save themselves.

[operating_line]

Just because a broker gives that excuse, I think they should hold them still unless it is written in black and white that no payoff is possible.

"Termination. Any liability of Parent and its successors and or assigns with respect to, and the obligation to pay, any Milestone Amounts, other than the Regulatory Milestone, or any directly related payments pursuant to this Agreement shall be terminated and of no force or effect upon the date that is 20 years after the date of this Agreement. Any liability of Parent and its successors and or assigns with respect to, and the obligation to pay, the Regulatory Milestone Amount or any directly related payments pursuant to this Agreement, shall be terminated and of no force or effect upon the expiration of the Menadione Patent Rights. This Agreement shall otherwise be terminated and of no force or effect and the parties hereto shall have no liability hereunder upon the later to occur of: (i) the date that is 20 years after the date of this Agreement; or (ii) the expiration of the Menadione Patent Rights. "


https://www.sec.gov/Archives/edgar/data/831547/000119312513295701/d568990dex23.htm




I was unable to move my CVRs from the original institution where I bought TLON shares. New broker accounts only want to hold tradeable securities. This forced the original institution to hold them in a non-tradeable 'account' (basically dormant for years) with some cash used as collateral.

there is another smaller milestone list for the US company that took over from Spectrum but the original above should apply to our CVRs.

[ErnieBilco]

Firsttrade just trashed the CVRs - 6 years no activity

[operating_line]

Any sales of Marqibo help to trigger the milestones for the TLON CVRs. CASI have marketing rights for Marqibo in China.

It will take time but as I can see Marqibo is not worthless. it is being progessed in the US and now apparently still in China.

Lets see if we get something from the CVRs next year or two.

[mc1005]

What does CASI have to do with the CVRs we have from Talon? Are the CVRs dead? or do they have potential to live again?

[operating_line]

CASI: A Change in Strategy

It looks like CASI is now planning to progress Marqibo in China. There is a hint they expect approval in China this year.


"CASI’s management sees its opportunity as long-term. We agree with CASI’s decision as it will likely result in the best combination of revenue growth and solid profitability while moderating capital needs over the intermediate term."

"While this change is significant, we believe that there is room for upside as the company moves its licensed and proprietary hematology portfolio closer to commercialization."

"We forecast $7.1m in Evomela sales for 2020 and total sales of $12.5 million assuming approval and commercialization for Marqibo and Zevalin."

https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2020/CASI-A-Change-in-Strategy-article/default.aspx

[FLY HIGH NOW]

We all have waited so long for our CVRs coming back ... we just pray and hope real good news coming now ... specially for Coronaviruses pandemic time ??????

[operating_line]

I also want to receive my investment back. Being realistic however, CASI indicate it is not profitable enough to progress currently. Acrotech may show them the way to profitability if their trials are successful but the timelines for our payments are not encouraging.

I give it about 20% chance at receiving anything back unfortunately.

here is a clinical trial that will give results in may 2021. I will check in then to see if there is any positive outlook.

https://clinicaltrials.ucsf.edu/trial/NCT02879643

[FLY HIGH NOW]

Does it mean we all Tlon investors will not have a chance to Recoup our money back ???!! Not saying profits or interest from investing in this Scamming TLON ??
Someone may Explain anyway better so all TLON investors can understand our CVRs better?

[operating_line]

No sign of progress yet

I believe the sales of Marqibo by Acrotech can trigger milestone payments of these secondary CVRs to Spectrum Pharma (or directly to the transfer agent managing our primary CVRs) if within the next four years only since:

"The milestone period lasts for five years post the closing of the transaction"

Similarly, CASI partners with Spectrum for the China region but I do not see any progress with clinical trials there for approval and generating sales.

"In March 2019, the Company received NMPA’s approval of the Company’s Clinical Trial Application (CTA) to allow for a trial to evaluate its efficacy and safety. However, due to the evolving standard of care environment, the rare and niche indication for this product, and our commitment to prioritize resources for our other programs, the Company considers this product to be non-core and is currently evaluating its options for this product."


https://www.casipharmaceuticals.com/product-pipeline/marqibo/

[FLY HIGH NOW]

When Spectrums sold Marqibo ...to Acrotech for $160 mil... we all Tlon investors should consider that it was Spectrum’s revenue from Marqibo and others related to TLON that we are Entitled to it for our CVRs plus Acrotech’s future revenues will be Distributed according to Tlon investors’ CVRs during guaranteed periods for our CVRs ??

[operating_line]

Information on CVR milestones was posted here:

https://www.streetinsider.com/Corporate+News/Spectrum+Pharma+%28SPPI%29+Sells+Marketed+Portfolio+to+Acrotech+Biopharma+for+%24160+Million+Plus+%24140+Million+in+Milestones/15015702.html

[operating_line]

Patience under uncertainty: also hoping for CVR distribution

Acrotech focussed on commercialization of oncology products in US market, including Marqibo
https://acrotechbiopharma.com/our-products/

It is unlikely they can advise us on the commercialization progress in any detail.

CASI betting on Chinese market for oncology products, including Marqibo. Still awaiting approval in this market.

https://www.fool.com/earnings/call-transcripts/2020/03/17/casi-pharmaceuticals-inc-casi-q4-2019-earnings-cal.aspx

[xlofer]

That is more than a year ago can you find out what is going On. Thanks

[FLY HIGH NOW]

I just talked to Askley 2/21/20 ( Spectrum Investors relations) , she said Spectrum sold Marquibo to AcroTech (866-850-2876) in Jan 2019, now our CVRs will Depend on sales of AcroTech
We can call AcroTech to see if they hit the milestone that will pay us our CVRs

[xlofer]

Thief hopefully they get bankrupt. You start we follow Up, let us know.

[FLY HIGH NOW]

We also call SEC to Complain about TLON CVR too ...what has Big Pharma Spectrum done secretly about TLON investors’ money ???

We TLON investors or our lawyers can Call investor relations of Spectrum Pharma: 949-788-6700 or 949-743-9244 to see what Spectrum pharma has done with our money ??

[FLY HIGH NOW]

That is a good and clear name for TLON investors and others related to TLON investments/ business transactions ??

why have TLON investors waited so long to get our money back ? Anyone here have known anything about it ? What can we do and should get it done by now to get our money back ??? Our lawyers should call pharmaceutical pharma Spectrum.... to find out their revenues and to Audit their Account statements...???

[FLY HIGH NOW]

We should have a class action lawsuits together to let courts, lawyers... to review their financial statements... why their investors not got their deserved money yet? They will get ...punitive verdicts ... if they haven’t done it right ways for their investors, customers...

[CVR Investor]

Yes we should fight for it. I'm still trying to figure out how to get the money. Was it suppose to in 2020 or now? I think like you said have someone review what we are supposed to get since the companies have change hands so many times.

[FLY HIGH NOW]

We haven’t received any money in our brokers accounts yet? Anyone have seen your money yet in your brokers accounts...??
Do we need to ask our lawyers to review their Company’s account statements for any profits/ revenues from TLON products?
We all TLON investors need to fight for our rights and money back????????????????

[upanddown66]

The Spectrum CVR are now renamed to TALON THERAPEUTICS CVR... a/o any idea with that?

[xlofer]

Still waiting, hopefully we will see something, talk to someone if you know or maybe call SPPI investor relation ask if they have any News.

[FLY HIGH NOW]

We should have some money back for our TLON investment right? They hide / steal our money away??
Anyone here talked to your lawyers ??

[xlofer]

R we ever gonna see anything out of SPPI

[FLY HIGH NOW]

we hope to get our money back soon....we also hope that we don't have to need our lawyers to review their past revenues statements to see profits for TLON ...God bless TLON CURING many needed people across the globe

[xlofer]

I still hope one day we will get something from these crooks

[FLY HIGH NOW]

Anyone know any revenues about TLON? where are our money? do we need our lawyers... to investigate the revenues of TLON? they can run...but not hide

[FLY HIGH NOW]

Anyone knows anything about our money from TLON? please post it up here ! what we all can do to get our money? God please bless and help us now because we have waited for our money back too long!

[xlofer]

Do we ever gonna see our Money.

[operating_line]

Marqibo sold to Acrotech Biopharma, subsidiary of Aurobindo


https://www.streetinsider.com/Corporate+News/Spectrum+Pharma+%28SPPI%29+Sells+Marketed+Portfolio+to+Acrotech+Biopharma+for+%24160+Million+Plus+%24140+Million+in+Milestones/15015702.html

https://www.pharmaceutical-business-review.com/news/acrotech-hematology-oncology-spectrum/

Marqibo Milestones
$30 million for FDA Product Approval for MARQIBO with label indicated for diffuse large B-cell lymphoma
$10 million for FDA Product Approval for MARQIBO for any indication other than the B-Cell Lymphoma Indication, single vial or pediatric ALL
$30 million for Net Sales of MARQIBO during any trailing twelve (12) month period during the Milestone Period are equal to or greater than $300,000,000
$10 million for Net Sales of MARQIBO during any trailing twelve (12) month period during the Milestone Period are equal to or greater than $400,000,000

[operating_line]

If you did not receive that cash and see the CVRs in your account, try to contact your broker and enquire why it was not received. They can follow up with Corporate Stock Transfer, Inc.

https://www.businesswire.com/news/home/20130717005490/en/Spectrum-Pharmaceuticals-Acquires-Talon-Therapeutics

[operating_line]

My guess is 2020 could be possible but try to follow the revenue against milestone payments in the CVR terms.

[bmatt]

Haven't been here for years. Any help me on how people were paid out for the base $.05 a share?

[xlofer]

R we ever will see any Money. Anyone.

[operating_line]

Spectrum Pharmaceuticals Q3 2018: MARQIBO® net sales of $1.1 million

https://sg.finance.yahoo.com/news/spectrum-pharmaceuticals-reports-third-quarter-210000858.html

[operating_line]

CASI Pharmaceuticals To Build GMP Manufacturing Site

https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-build-gmp-manufacturing-site-in-wuxi-china-300751946.html

CFDA review in progress for MARQIBO®
https://www.streetinsider.com/SEC+Filings/Form+8-K+CASI+Pharmaceuticals%2C+For%3A+Nov+14/14826989.html

[operating_line]

CASI funding and new CFO

"to help transition the Company's financial operations to commercial stage as we launch EVOMELA® and other additional products from our pipeline

https://www.gurufocus.com/news/746156/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer

https://www.marketwatch.com/press-release/casi-pharmaceuticals-announces-485-million-private-placement-2018-09-14

Summary of status with Marqibo

Highest Development Phases
Marketed Precursor cell lymphoblastic leukaemia-lymphoma
Phase III Non-Hodgkin's lymphoma
Phase I/II Cancer
Preclinical Multiple myeloma
Discontinued Colorectal cancer; Malignant melanoma; Pancreatic cancer; Small cell lung cancer

Most Recent Events
14 Aug 2018 CASI Pharmaceuticals expects that the CFDA will complete the review of Marqibo’s import drug clinical trial application within the next four to six months
24 Jun 2018 Biomarkers information updated
26 May 2017 Phase II development for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) is ongoing in USA

[operating_line]

You have the CVR payment schedule information from when the company was acquired. We are currently far off revenue required for TLON shareholders to receive milestone payments. I hope to see milestones hit within a couple of years but have not seen signs of this being likely yet.

http://www.casipharmaceuticals.com/investor-relations/news/casi-pharmaceuticals-announces-second-quarter-and-first-half-2018

"CASI continues to work with the CFDA on advancing Marqibo’s import drug clinical trial application and anticipates that the regulatory agency will complete its review within the next four to six months."

Marqibo could be entering the Chinese market next February.

[FLY HIGH NOW]

What at least their revenues we Tlon shareholders can have some money??

[operating_line]

Q1 2018 MARQIBO® net sales of $0.9 million
https://seekingalpha.com/article/4184986-can-spectrum-pharmaceuticals-continue-rally

Possible sale of Spectrum Pharmaceuticals, Inc?
https://www.fiercepharma.com/hematology-and-oncology-drugmaker-spectrum-looks-at-potential-sale-bloomberg

[FLY HIGH NOW]

YES ,we hope Marqibo really help many and many patients in china and around the globe and become milestone for its treatment! God bless Marqibo and its patients!

[operating_line]

CASI have cash reserves to commercialize Marqibo in China and confirmed it is seeking regulatory approval there.

http://www.casipharmaceuticals.com/investor-relations/news/casi-pharmaceuticals-announces-50-million-private-placement-to-prepare

[operating_line]

Q1 2018: Spectrum Pharma- $0.9m net sales Marqibo
http://www.digitaljournal.com/pr/3760426

[FLY HIGH NOW]

https://asia.nikkei.com/Business/Trends/China-sees-influx-of-blockbuster-drugs-as-market-grows
How has Marqibo done in China and Asia markets?